Ipamorelin dosage in research protocols typically starts at 200–300 mcg per injection, administered subcutaneously before sleep, in 3–6 month cycles. This guide walks through how ipamorelin works, what current research says about dosing and timing, and what a provider-supervised evaluation looks like.
If you've been exploring growth hormone peptides, ipamorelin comes up quickly. It's one of the more studied growth hormone secretagogues — a class of compounds that prompt the pituitary gland to release growth hormone pulses rather than supplying exogenous GH. The protocol mechanics matter here. Get them right, and the timing works with your body's natural rhythms. Get them wrong, and you're wasting the compound's narrow action window.
Ipamorelin is not FDA-approved. It is a compounded peptide prepared under federal compounding regulations and is available only subject to medical approval by a licensed provider.
Step 1: Understand What Ipamorelin Is and How It Works
Ipamorelin is a synthetic pentapeptide — a five-amino-acid chain — that acts as a selective growth hormone secretagogue (GHS). It binds to the ghrelin receptor (GHSR) on pituitary cells and stimulates pulsatile growth hormone release without significantly affecting cortisol, prolactin, or ACTH. That selectivity is the key distinguishing feature.
A 1998 study in European Journal of Endocrinology by Raun et al. established ipamorelin's profile: it produced dose-dependent GH secretion with a favorable selectivity pattern compared to earlier GHRPs. Research since has explored its potential in tissue recovery models, sleep quality, and body composition, though human clinical trials remain limited.
Its half-life is approximately 2 hours, making timing critical for aligning ipamorelin's activity window with your body's own peak GH release — which naturally occurs in the first hours of sleep.
Step 2: Know the Difference Between Ipamorelin and Related Peptides
Ipamorelin is often compared to sermorelin and CJC-1295. Understanding the differences helps clarify where it fits in a protocol:
| Peptide | Mechanism | Half-Life | Selectivity | Common Combination |
|---|---|---|---|---|
| Ipamorelin | GHRP — binds ghrelin receptor, stimulates GH pulse | ~2 hours | High (minimal cortisol/prolactin effect) | Often stacked with CJC-1295 |
| Sermorelin | GHRH analog — mimics natural GH-releasing hormone | ~10-20 min | Moderate | Used solo or in combinations |
| CJC-1295 | GHRH analog with extended half-life (DAC form) | Days (DAC) / hours (no-DAC) | High | Stacked with ipamorelin |
| MK-677 (Ibutamoren) | Oral ghrelin mimetic — non-peptide GHS | ~24 hours | Moderate (may raise cortisol) | Oral alternative |
Ipamorelin's selectivity is the main reason it's frequently chosen for standalone use — it delivers GH stimulation without the cortisol spike that some older GHRPs can produce. See our full overview of CJC-1295 and Ipamorelin as a combined stack.
Step 3: Determine If You're a Candidate — Subject to Provider Evaluation
Ipamorelin is not appropriate for everyone. General research indicates it's most explored in contexts involving age-related GH decline, sleep disruption affecting recovery, and body composition goals in otherwise healthy adults. It's not studied for use in active cancers, certain endocrine disorders, or pregnancy.
A provider evaluation at TelosRX is asynchronous — you complete a medical intake form, and a licensed provider reviews your history and goals before any protocol is issued. No scheduled call required. This step is mandatory; ipamorelin requires a provider-issued prescription and no protocol begins without provider approval.
Step 4: Understand the Research-Supported Dosage Range
Research protocols have explored a dosage range of 100–300 mcg per injection. Most protocols used in clinical settings cluster around 200–300 mcg as the per-injection dose. This is a guidance range derived from available studies — actual dosing for any individual is determined by a licensed provider based on your specific profile.
- Starting range: 100–200 mcg per injection
- Maintenance range: 200–300 mcg per injection
- Frequency: Once daily in most protocols; some research used twice-daily dosing
- Route: Subcutaneous injection (fatty tissue, typically abdomen or thigh)
Doses beyond 300 mcg per injection do not appear to produce proportional additional GH release based on available data — a concept called "bell-curve" saturation at the pituitary receptor level. Higher doses are not documented to be more effective and may increase side effect likelihood.
Step 5: Time Injections to Align With Natural GH Patterns
Timing is where ipamorelin's 2-hour half-life becomes operationally important. Growth hormone is secreted in pulses, with the most significant pulse occurring during slow-wave sleep (typically 60–90 minutes after falling asleep).
Administering ipamorelin 30–60 minutes before bed is the standard approach in research protocols for this reason — the goal is for peak ipamorelin activity to coincide with the body's largest natural GH pulse. This timing is also supported by avoiding food for 2 hours before injection, since elevated insulin levels after meals can blunt GH secretion.
For protocols using twice-daily dosing, the second injection is commonly placed upon waking, before breakfast. This targets the smaller morning GH pulse. Check with your provider before adding a second daily injection.
Step 6: Structure an Appropriate Cycle
Continuous long-term use without cycling may reduce pituitary sensitivity over time. Research protocols and clinical practice commonly use:
- Cycle length: 3–6 months on
- Off period: 4–8 weeks before repeating
- Rationale: Allows pituitary GH-secreting cells to maintain baseline sensitivity to endogenous GH-releasing hormone
These cycle parameters are derived from available research and clinical experience with GH secretagogues as a class. Your provider will determine the appropriate cycle structure based on your goals and response, subject to evaluation.
For further reading on the research behind ipamorelin as part of a combined protocol, see the CJC-1295 and Ipamorelin stack research guide and the Sermorelin research guide.
Step 7: Know the Side Effect Profile
Ipamorelin's selectivity translates to a relatively clean side effect profile compared to growth hormone releasing peptides as a class compared to older GHRPs. Documented effects in research include:
- Transient water retention: Particularly in early weeks, as GH promotes sodium and water retention
- Mild headaches or dizziness: Reported in early-stage use, typically resolving
- Injection site reactions: Local redness or swelling, common with any subcutaneous peptide
- Fatigue: Some users report increased drowsiness, consistent with the sleep-aligned timing
Unlike GHRP-2 or GHRP-6, ipamorelin does not significantly stimulate cortisol or prolactin release at standard doses, based on the original Raun 1998 selectivity data. It also does not cause the pronounced appetite stimulation associated with ghrelin-activating peptides at higher doses. If you experience unexpected side effects, report them promptly to your provider.
Frequently Asked Questions
What is ipamorelin and what does it do?
Ipamorelin is a synthetic five-amino-acid peptide that acts as a selective growth hormone secretagogue. It binds to ghrelin receptors on the pituitary gland, stimulating pulsatile growth hormone release without significantly elevating cortisol or prolactin. It's studied in contexts including body composition, sleep quality, and recovery. It is not FDA-approved and is available only through a provider-issued prescription.
What is the standard ipamorelin dosage?
Research protocols have used 100–300 mcg per injection, with 200–300 mcg being the most common research range. Actual dosing for any individual is determined by a licensed provider based on your specific history and goals. No protocol begins without medical approval by a licensed provider.
When should I inject ipamorelin?
Most protocols time ipamorelin administration 30–60 minutes before bed. This aligns the peptide's ~2-hour activity window with the body's largest natural GH pulse, which occurs in early slow-wave sleep. A fasted state (no food for ~2 hours before injection) further supports GH release by keeping insulin low.
How long is an ipamorelin cycle?
Research protocols and clinical practice commonly use cycles of 3–6 months, followed by a 4–8 week off-period. Cycling helps maintain pituitary GH-receptor sensitivity over time. Your provider determines the cycle structure appropriate for your situation, subject to evaluation.
What are the side effects of ipamorelin?
Common effects include transient water retention in early weeks, mild headaches or dizziness, injection site reactions, and increased drowsiness tied to sleep-time administration. Ipamorelin has a favorable selectivity profile and typically does not cause significant cortisol elevation or appetite stimulation at standard doses. Report any unexpected effects to your provider promptly.
Can I stack ipamorelin with other peptides?
Ipamorelin is frequently studied in combination with CJC-1295 as a complementary GHRH+GHRP stack. The rationale is that GHRH analogs (CJC-1295) and GHRPs (ipamorelin) act on different receptors, with synergistic effects on GH pulse amplitude. Any stacking protocol requires provider evaluation and approval. See the CJC-1295 and Ipamorelin research guide for details.
Is ipamorelin safe?
Available research shows a relatively favorable tolerability profile for ipamorelin, particularly compared to older growth hormone releasing peptides. Long-term safety data in humans is limited. All use is subject to medical approval by a licensed provider, and ipamorelin is not appropriate for everyone. It is not FDA-approved and is a compounded peptide prepared under federal compounding regulations.
How does ipamorelin compare to sermorelin?
Ipamorelin acts as a GHRP (binds ghrelin receptor), while sermorelin is a GHRH analog (mimics growth hormone releasing hormone). They work through different receptors and have different half-lives. Ipamorelin has a longer half-life (~2 hours vs. ~10-20 minutes for sermorelin) and higher selectivity for GH vs. cortisol/prolactin. A provider can evaluate which approach fits your goals, subject to medical approval.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.